Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Feasibility Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Stage III Melanoma Patients

X
Trial Profile

Feasibility Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Stage III Melanoma Patients

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms OpACIN
  • Most Recent Events

    • 24 Oct 2023 Results (n=86) assessing 4-yr event free survival rate in melanoma patients treated with ipilimumab plus nivolumab were presented at the 48th European Society for Medical Oncology Congress
    • 18 Jan 2023 Results assessing survival rate in the OpACIN and OpACIN-neo trials published in the Annals of Oncology
    • 13 Sep 2022 Results from three clinical studies (OpACIN, OpACIN-neo and PRADO) assessing clinical and tumor characteristics of patients with recurrence after pathologic response presented at the 47th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top